|
Market Closed -
Nasdaq
20:00:00 26/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 10.00 USD | -0.40% |
|
+16.01% | +29.53% |
| 10-15 | Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says | MT |
| 10-15 | Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating | MT |
Company Valuation: Verastem, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 373.5 | 84.56 | 205.7 | 230.1 | 595.8 | 1,215 | - | - |
| Change | - | -77.36% | 143.23% | 11.87% | 158.95% | 103.91% | - | - |
| Enterprise Value (EV) 1 | 373.5 | 84.56 | 205.7 | 230.1 | 595.8 | 1,027 | 1,215 | 1,215 |
| Change | - | -77.36% | 143.23% | 11.87% | 158.95% | 72.31% | 18.34% | 0% |
| P/E | -5x | -1.06x | -2.06x | -1.41x | -2.56x | -6.18x | -7.49x | -10.5x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.14x | 0.2x | 0.19x | 0.1x | 0.1x | 0.4x | 0.4x |
| Capitalization / Revenue | 182x | 32.6x | - | 23x | 19.3x | 10.9x | 7.63x | 4.98x |
| EV / Revenue | 182x | 32.6x | - | 23x | 19.3x | 9.22x | 7.63x | 4.98x |
| EV / EBITDA | - | - | - | -2x | - | -5.66x | -7.89x | -7.61x |
| EV / EBIT | -6.08x | -1.16x | -2.23x | -2x | -3.5x | -5.79x | -6.71x | -8.76x |
| EV / FCF | - | - | -2.38x | -2.2x | -4.05x | -6.13x | -7.48x | -9.92x |
| FCF Yield | - | - | -42% | -45.5% | -24.7% | -16.3% | -13.4% | -10.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -4.92 | -4.56 | -3.96 | -3.66 | -3.02 | -1.619 | -1.334 | -0.9567 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2.053 | 2.596 | - | 10 | 30.91 | 111.3 | 159.2 | 244.2 |
| EBITDA 1 | - | - | - | -114.9 | - | -181.4 | -153.9 | -159.6 |
| EBIT 1 | -61.41 | -72.94 | -92.08 | -115 | -170.1 | -177.4 | -181 | -138.6 |
| Net income 1 | -71.2 | -73.81 | -87.37 | -130.6 | -209.5 | -170.4 | -178.6 | -130.2 |
| Net Debt 1 | - | - | - | - | - | -188.3 | - | - |
| Reference price 2 | 24.60 | 4.83 | 8.14 | 5.17 | 7.72 | 10.00 | 10.00 | 10.00 |
| Nbr of stocks (in thousands) | 15,182 | 17,508 | 25,268 | 44,507 | 77,182 | 121,501 | - | - |
| Announcement Date | 28/03/22 | 14/03/23 | 14/03/24 | 20/03/25 | 04/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.18x | 9.22x | -5.66x | - | 1.22B | |
| 18.07x | 6.54x | 12.9x | 1.78% | 65.28B | |
| 30.04x | 7.96x | 26.09x | 0.05% | 54.57B | |
| 36.97x | 6.56x | 19.6x | 0.88% | 53.59B | |
| 34.86x | 3.39x | 14.64x | -.--% | 45.03B | |
| 48.82x | 5.62x | 30.9x | -.--% | 42.17B | |
| -19.09x | 184.46x | -20.29x | -.--% | 39.42B | |
| 28.28x | 8.04x | 20.81x | 0.38% | 32.71B | |
| 27.72x | 5.84x | 15.15x | -.--% | 24.01B | |
| 36.39x | 6.61x | 22.07x | -.--% | 26.5B | |
| Average | 23.59x | 24.43x | 13.62x | 0.34% | 38.45B | |
| Weighted average by Cap. | 26.59x | 24.61x | 15.87x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VSTM Stock
- Valuation Verastem, Inc.
Select your edition
All financial news and data tailored to specific country editions
